SEC Form DEF 14A filed by Traws Pharma Inc.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Securities Exchange Act of 1934
![[MISSING IMAGE: lg_trawspharma-4clr.jpg]](https://www.sec.gov/Archives/edgar/data/0001130598/000110465925097926/lg_trawspharma-4clr.jpg)
12 Penns Trail
Newtown, PA 18940 USA
(267) 759-3680
Chief Executive Officer
October 8, 2025
| | | | | 1 | | | |
| | | | | 8 | | | |
| | | | | 21 | | | |
| | | | | 32 | | | |
| | | | | 33 | | | |
| | | | | 34 | | | |
| | | | | 36 | | | |
| | | | | 38 | | | |
| | | | | 41 | | | |
| | | | | 43 | | | |
| | | | | 49 | | | |
| | | | | 54 | | | |
| | | | | A-1 | | |
![[MISSING IMAGE: lg_trawspharma-4clr.jpg]](https://www.sec.gov/Archives/edgar/data/0001130598/000110465925097926/lg_trawspharma-4clr.jpg)
ANNUAL MEETING OF STOCKHOLDERS TO BE HELD NOVEMBER 21, 2025
Name
|
| |
Age
|
| |
Position(s) with Traws Pharma, Inc.
|
| |
Served as
Director From |
|
Iain Dukes, D. Phil. | | |
67
|
| |
Director, Chief Executive Officer and Secretary
|
| |
2024
|
|
Jack E. Stover | | |
72
|
| |
Chairman
|
| |
2016
|
|
Werner Cautreels, Ph.D. | | |
72
|
| |
Director
|
| |
2024
|
|
Nikolay Savchuk, Ph.D. | | |
56
|
| |
Director and Chief Operating Officer
|
| |
2024
|
|
Trafford Clarke, Ph.D. | | |
67
|
| |
Director
|
| |
2022
|
|
M. Teresa Shoemaker | | |
64
|
| |
Director
|
| |
2020
|
|
John Leaman, M.D. | | |
52
|
| |
Director
|
| |
2025
|
|
Name
|
| |
Age
|
| |
Position(s) with Traws Pharma, Inc.
|
|
Iain Dukes, D. Phil. | | |
67
|
| |
Chief Executive Officer, Secretary and Director
|
|
Charles Parker | | |
45
|
| |
Chief Financial Officer
|
|
Victor Moyo, M.D. | | |
57
|
| |
Chief Medical Officer, Oncology
|
|
C. David Pauza, Ph.D. | | |
71
|
| |
Chief Science Officer, Virology
|
|
Robert R. Redfield, M.D. | | |
74
|
| |
Chief Medical Officer
|
|
Nikolay Savchuk, Ph.D. | | |
56
|
| |
Chief Operating Officer and Director
|
|
Name
|
| |
Fees Earned or
Paid in Cash ($) |
| |
Stock
Option Awards ($)(1)(2) |
| |
All Other
Compensation ($) |
| |
Total ($)
|
| ||||||||||||
Peter Atadja, Ph.D.(3)
|
| | | | 26,000 | | | | | | — | | | | | | — | | | | | | 26,000 | | |
Jerome E. Groopman, M.D.(3)
|
| | | | 11,000 | | | | | | — | | | | | | — | | | | | | 11,000 | | |
Viren Mehta, Pharm.D.(3)
|
| | | | 25,750 | | | | | | — | | | | | | — | | | | | | 25,750 | | |
James J. Marino(4)
|
| | | | 82,500 | | | | | | — | | | | | | — | | | | | | 82,500 | | |
Luba Greenwood(5)
|
| | | | — | | | | | | 166,293 | | | | | | — | | | | | | 166,293 | | |
Trafford Clarke, Ph.D.
|
| | | | 45,000 | | | | | | 58,991 | | | | | | — | | | | | | 103,991 | | |
M. Teresa Shoemaker
|
| | | | 59,000 | | | | | | 58,991 | | | | | | — | | | | | | 117,991 | | |
Jack E. Stover
|
| | | | 117,500 | | | | | | 108,991 | | | | | | — | | | | | | 226,491 | | |
Traws Pharma, Inc.
12 Penns Trail
Newtown, PA 18940
APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF A FREQUENCY OF “EVERY TWO YEARS” OF ADVISORY VOTES ON THE COMPENSATION OF OUR NAMED
EXECUTIVE OFFICERS
Fee Category
|
| |
Fiscal 2024
|
| |
Fiscal 2023
|
| ||||||
Audit Fees(1)
|
| | | $ | 720,000 | | | | | $ | 326,000 | | |
Audit-Related Fees(2)
|
| | | | — | | | | | | — | | |
Tax Fees(3)
|
| | | | — | | | | | | — | | |
Total Fees
|
| | | $ | 720,000 | | | | | $ | 326,000 | | |
ADDITIONAL VOTES
M. Teresa Shoemaker
Trafford Clarke
John Leaman*
Name and Address of Beneficial Owner
|
| |
Number of Shares
Beneficially Owned |
| |
Percentage of Shares
Beneficially Owned |
| ||||||
5% or greater stockholders: | | | | | | | | | | | | | |
Viriom, Inc.(1)
|
| | | | 1,628,581 | | | | | | 19.9% | | |
OrbiMed Advisors LLC(2)
|
| | | | 1,278,471 | | | | | | 16.4% | | |
Ikarian Healthcare Master Fund, L.P.(3)
|
| | | | 589,502 | | | | | | 7.3% | | |
Perceptive Advisors LLC(4)
|
| | | | 545,197 | | | | | | 7.5% | | |
Ayrton Capital LLC(5)
|
| | | | 403,650 | | | | | | 5.4% | | |
Squadron Master Fund LP(6)
|
| | | | 372,374 | | | | | | 5.2% | | |
Directors, Director Nominees and Named Executive Officers:
|
| | | | | | | | | | | | |
Iain Dukes, D.Phil.(7)
|
| | | | 233,308 | | | | | | 3.2% | | |
Charles Parker
|
| | | | — | | | | | | — | | |
Werner Cautreels, Ph.D.(8)
|
| | | | 98,348 | | | | | | 1.4% | | |
Trafford Clarke, Ph.D.(9)
|
| | | | 21,106 | | | | | | * | | |
Nikolay Savchuk, Ph.D.(10)
|
| | | | 659,294 | | | | | | 8.8% | | |
M. Teresa Shoemaker(11)
|
| | | | 21,753 | | | | | | * | | |
Jack E. Stover(12)
|
| | | | 19,283 | | | | | | * | | |
John Leaman
|
| | | | — | | | | | | — | | |
Steven M. Fruchtman, M.D.(13)
|
| | | | 2,992 | | | | | | * | | |
Mark P. Guerin(14)
|
| | | | 11,195 | | | | | | * | | |
Victor Moyo, M.D.(15)
|
| | | | 2,605 | | | | | | * | | |
All current executive officers, directors and director nominees as a group (11 persons)(16)
|
| | | | 1,096,952 | | | | | | 14.0% | | |
Name and Principal Position
|
| |
Year
|
| |
Salary ($)
|
| |
Bonus ($)(1)
|
| |
Stock
Awards ($)(2) |
| |
Option
Awards ($)(3) |
| |
All Other
Compensation ($)(4) |
| |
Total ($)
|
| |||||||||||||||||||||
Werner Cautreels, Ph.D.(5)
Former Chief Executive Officer |
| | | | 2024 | | | | | | 445,769 | | | | | | — | | | | | | 200,000 | | | | | | — | | | | | | 1,813 | | | | | | 647,582 | | |
| | | 2023 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
Steven M. Fruchtman, M.D.(6)
Former President and Chief Executive Officer |
| | | | 2024 | | | | | | 332,887 | | | | | | — | | | | | | — | | | | | | — | | | | | | 77,113 | | | | | | 410,000 | | |
| | | 2023 | | | | | | 660,894 | | | | | | 227,391 | | | | | | 50,613 | | | | | | 131,662 | | | | | | 36,187 | | | | | | 1,106,747 | | | ||
Mark P. Guerin(7)
Former Chief Financial Officer and Chief Operating Officer |
| | | | 2024 | | | | | | 520,850 | | | | | | — | | | | | | — | | | | | | — | | | | | | 41,898 | | | | | | 562,747 | | |
| | | 2023 | | | | | | 500,687 | | | | | | 137,809 | | | | | | 18,980 | | | | | | 50,247 | | | | | | 36,985 | | | | | | 744,709 | | | ||
Victor Moyo, M.D.(8)
Chief Medical Officer – Oncology |
| | | | 2024 | | | | | | 453,107 | | | | | | — | | | | | | — | | | | | | — | | | | | | 25,329 | | | | | | 478,436 | | |
| | | 2023 | | | | | | 103,846 | | | | | | 113,990 | | | | | | — | | | | | | 78,616 | | | | | | 108,226 | | | | | | 404,678 | | |
| | | Summary Compensation Table Total for PEO 1 ($) | | | Summary Compensation Table Total for PEO 2 ($) | | | Average Summary Compensation Table Total Compensation for Non-PEO NEOs ($) | | | Compensation Actually Paid to PEO 1 ($) | | | Compensation Actually Paid to PEO 1 ($) | | | Average Compensation Actually Paid to Non-PEO NEOs ($) | | | Value of Initial Fixed $100 Investment Based on Total Shareholder Return ($) | | | GAAP Net Loss ($) | | ||||||||||||||||||||||||
Fiscal Year | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
2024(1) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ( | | | |||||||
2023(2) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ( | | | |||||||
2022(3) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ( | | |
| | | Summary Compensation Table Total Compensation ($) | | | Value of Equity Awards Deducted from SCT ($) | | | Fair Value of Equity Awards Compensation Granted in Current Year ($)(1) | | | Year-Over- Year Change in Fair Value of Unvested Equity Awards ($)(2) | | | Year-Over-Year Change in Fair Value of Equity Awards Vested During the Year ($)(3) | | | Prior Year-End Fair Value of Equity Awards Forfeited in the Year ($) | | | Compensation Actually Paid ($) | | |||||||||||||||||||||
PEO 1 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
2024 | | | | | | | | | | | | | | | | | | | | ( | | | | | | | | | | | ( | | | | | | | | |||||
2023 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||
2022 | | | | | | | | | | | | | | | | | | | | ( | | | | | | ( | | | | | | | | | | | | | |||||
PEO 2 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
2024 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||
Average Non-PEO NEOs | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||
2024 | | | | | | | | | | | | | | | | | | | | ( | | | | | | ( | | | | | | | | | | | | | |||||
2023 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 623,539 | | | ||||||
2022 | | | | | | | | | | | | | | | | | | | | ( | | | | | | ( | | | | | | | | | | | | |
| | |
Option Awards
|
| |
Stock Awards
|
| ||||||||||||||||||||||||||||||||||||||||||
Name(1)
|
| |
Number of
Securities Underlying Unexercised Options Exercisable (#) |
| |
Number of
Securities Underlying Unexercised Options Unexercisable (#) |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| |
Number of
Shares or Units of Stock That Have Not Vested (#) |
| |
Market
Value of Shares or Units of Stock That Have Not Vested ($) |
| |
Equity Incentive
Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) |
| |
Equity Incentive
Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) |
| ||||||||||||||||||||||||
Cautreels
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | 8,000(2) | | | | | | 200,000 | | | | | | | | | | | | | | |
Guerin
|
| | | | 1 | | | | | | — | | | | | | 130,500.00 | | | | | | 4/16/2025 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 1 | | | | | | — | | | | | | 83,250.00 | | | | | | 9/25/2025 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 1 | | | | | | — | | | | | | 36,562.50 | | | | | | 1/26/2026 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 1 | | | | | | — | | | | | | 36,562.50 | | | | | | 1/26/2026 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 1 | | | | | | — | | | | | | 18,225.00 | | | | | | 9/1/2026 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 2 | | | | | | — | | | | | | 18,225.00 | | | | | | 9/1/2026 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 1 | | | | | | — | | | | | | 14,906.25 | | | | | | 12/15/2026 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 4 | | | | | | — | | | | | | 15,187.50 | | | | | | 1/17/2027 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 6 | | | | | | — | | | | | | 8,437.50 | | | | | | 1/3/2028 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 69 | | | | | | — | | | | | | 2,587.50 | | | | | | 7/26/2028 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 174 | | | | | | — | | | | | | 116.25 | | | | | | 12/20/2029 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 1,448(3) | | | | | | — | | | | | | | | | | | | 7/9/2030 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 803(3) | | | | | | — | | | | | | | | | | | | 2/17/2031 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 1,710 | | | | | | — | | | | | | 129.75 | | | | | | 8/2/2031 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 2,346(4) | | | | | | 138 | | | | | | 45.50 | | | | | | 2/7/2032 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 1,675(4) | | | | | | 335 | | | | | | 33.25 | | | | | | 6/10/2032 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 1,844(4) | | | | | | 1,316 | | | | | | 18.25 | | | | | | 3/13/2033 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 322(5) | | | | | | 2,711 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,190(6) | | | | | | 32,539 | | |
Moyo
|
| | | | 1,459(7) | | | | | | 3,541 | | | | | | 17.79 | | | | | | 10/2/2033 | | | | | | | | | | | | | | | | | | | | | | | | | | |
Plan Category
|
| |
Number of Shares
to be Issued Upon Exercise of Outstanding Options, Warrants and Rights |
| |
Weighted-Average
Exercise Price of Outstanding Options, Warrants and Rights |
| |
Number of Shares
Remaining Available for Future Issuance Under the Equity Compensation Plan (Excluding Shares in First Column) |
| | |||||||||||
Equity compensation plans approved by stockholders
|
| | | | 119,523(1) | | | | | $ | 40.19(2) | | | | | | 296,400(3) | | | | ||
Equity compensation plans not approved by stockholders
|
| | | | 386,747(4) | | | | | $ | 1.24(2) | | | | | | — | | | | ||
Total
|
| | | | 506,270 | | | | | | | | | | | | 296,400 | | | | | |
Chief Executive Officer
![[MISSING IMAGE: px_25trawsproxy1pg01-bw.jpg]](https://www.sec.gov/Archives/edgar/data/0001130598/000110465925097926/px_25trawsproxy1pg01-bw.jpg)
![[MISSING IMAGE: px_25trawsproxy1pg02-bw.jpg]](https://www.sec.gov/Archives/edgar/data/0001130598/000110465925097926/px_25trawsproxy1pg02-bw.jpg)